Moreover, patients with melanoma with high C5orf58 expression who received single anti-PD-1 monotherapy or anti-CTLA-4 monotherapy also showed a worse drug response, resulting in worse progression-free survival (Figures 8B, C). Here, PDCD1 is linked to melanoma.